First off I have never made that claim about not having enough money for a phase III trial or being cash flow positive. So whatever you're trying to argue with me about is null and void. Any savvy investor would realize those things would get done or happen.
The claim about getting 100, 200, or 300 million is just an assumption as is mine about getting much less than that. But which one makes more sense. A company that has never had a product make more than 10 million annually. It will also be their first ADT on the market and is suspect to having low market share, as first year products tend to be on the the lower percentiles of market share. Once they are on the market a couple more years, if the product has potential it begins to gain more and more market share.
So saying a first year product will garner 100-300 million is ludicrous even though the competition has lousy products, the companies marketing them are much larger and more notable than Elite and their products have been prescribed a lot longer than Elites.
So if eli200 doesn't bring in those revenues which is expected, how do we get to all these price per shares thrown around in the multiple dollars while were still on the OTC? Big time institutions don't invest in microcap OTC stocks. Also pps is irrelevant when you mention its only .20. Its all about the market cap and share structure. Elite has over 150million market cap and sitting at .20, now that is much different than saying, oh, well its a .20 cent stock the skies the limit. I much rather invest in a 3$ stock with a 70 million dollar market cap that has a low share structure and low float and trading on a higher exchange with big institutions having a huge position. Price per share is a novice take on deciding if it's undervalued or not
